Sugi Predict

Sugi Predict / Compounds / SCHEMBL2804512

SCHEMBL2804512

SCHEMBL2804512

NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLO1 Q04760 2/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ GSTK1 Q9Y2Q3 1/20 0.49
▸ BMP1 P13497 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ KMT2A Q03164 2/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ PMP22 Q01453 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CA2 P00918 2/20 0.33
▸ CA1 P00915 1/20 0.33
▸ GNPAT O15228 1/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.33
▸ DPP9 Q86TI2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8494001 1.00 GLO1 (0.49) GLO1PTGS1GSTK1BMP1ALDH1A1
SCHEMBL29630368 0.92 GLO1 (0.44) GLO1PTGS1GSTK1BMP1
SCHEMBL6863995 0.91 GLO1 (0.45) GLO1PTGS1GSTK1BMP1ALDH1A1
SCHEMBL2804509 0.90 PTGS1 (0.51) GLO1PTGS1GSTK1BMP1ALDH1A1
SCHEMBL29050824 0.90 PTGS1 (0.51) GLO1PTGS1GSTK1BMP1ALDH1A1
SCHEMBL30563273 0.89 GLO1 (0.44) GLO1PTGS1GSTK1BMP1ALDH1A1
SCHEMBL30170524 0.88 GLO1 (0.44) GLO1PTGS1GSTK1BMP1FOLH1
SCHEMBL30170441 0.88 GLO1 (0.44) GLO1PTGS1GSTK1BMP1FOLH1
SCHEMBL22111148 0.88 GLO1 (0.49) GLO1PTGS1GSTK1BMP1ALDH1A1
SCHEMBL32670748 0.88 GLO1 (0.49) GLO1PTGS1GSTK1BMP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 — — US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 — — US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 — — US claimed
EP-2207525-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'Oréal (FR) 2010-07-21 — — EP claimed
EP-2205201-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'Oreal (FR) 2010-07-14 — — EP claimed
WO-2009053594-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 — — WO claimed
WO-2009053587-A2 COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 — — WO claimed
WO-2009053584-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 — — WO claimed
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-26 — — US disclosed
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-04-11 — — US disclosed
EP-4204100-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE L'OREAL (FR) 2023-07-05 — — EP disclosed
US-20230109312-A1 NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IGENICA BIOTHERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 — — US disclosed
WO-2022047081-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE HENRY DEREK (US) 2022-03-03 — — WO disclosed
EP-2008647-A1 Cosmetic or pharmaceutical composition comprising a condensation polymer, cosmetic treatment method, condensation polymer and preparation method L'Oreal (FR) 2008-12-31 — — EP disclosed
EP-0379606-B2 Novel transglutaminase AJINOMOTO KK (JP) 1999-07-28 — — EP disclosed
US-5252469-A Culturing the microorganism in the absence of calcium ion AMANO PHARMACEUTICAL CO., LTD. (JP) 1993-10-12 — — US disclosed
US-5156956-A Derived from microorganism; catalyzes protein gelation in absence of calcium AJINOMOTO CO., INC. (JP) 1992-10-20 — — US disclosed
US-5055310-A Reacting soy milk with solidifying agent and transglutaminase enzyme as catalyst AJINOMOTO CO., INC. (JP) 1991-10-08 — — US disclosed
EP-0379606-A1 Novel transglutaminase AJINOMOTO CO., INC. (JP) 1990-08-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 GLO1 3687/4885PTGS1 3990/4885GSTK1 3112/4885
US-20230109312-A1 NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SDCBP, DCLRE1A, BCR GLO1 2758/4885PTGS1 3783/4885GSTK1 1255/4885
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 GLO1 1432/4885PTGS1 1219/4885GSTK1 3253/4885
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 GLO1 3687/4885PTGS1 3990/4885GSTK1 3112/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA GLO1 371/4885PTGS1 717/4885GSTK1 3914/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA GLO1 382/4885PTGS1 3376/4885GSTK1 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.